Vitamin D Supplementation Requirement in Obese Subjects
Primary Purpose
Vitamin D Deficiency
Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Vitamin D3
placebo
Sponsored by
About this trial
This is an interventional treatment trial for Vitamin D Deficiency
Eligibility Criteria
Inclusion Criteria:
- Healthy men or women between the ages of 18 and 70 years old who are enrolled in our Weight Management Program with baseline BMI > 30 Kg/m2.
Exclusion Criteria:
- Pregnancy,
- Serum 25(OH)D level greater than 80 nmol/L,
- Hypercalcemia (serum calcium level greater than the upper limit of normal),
- Recent surgery or illness,
- Those with chronic use of medications that influence calcium/vitamin D metabolism such as anti-convulsants, lithium and steroids. Thiazide diuretics for hypertension will be acceptable.
- Subjects with sarcoidosis will be excluded.
- Those who do not qualify to participate in the Weight Management Program will be excluded. They include subjects with active substance abuse and unstable cardiac disease.
Sites / Locations
- Winthrop University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Active Comparator
Arm Label
Placebo
Vitamin D3
Arm Description
Half of subjects will be randomized to the placebo group.
This is the study group that receives Vitamin D supplementation.
Outcomes
Primary Outcome Measures
Mean Level of 25(OH)D
Vitamin D (25(OH)D) level at Baseline.
Mean Level of 25(OH)D
Vitamin D (25(OH)D) level at Month 2.
Secondary Outcome Measures
Full Information
NCT ID
NCT00996866
First Posted
October 15, 2009
Last Updated
June 12, 2023
Sponsor
Winthrop University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT00996866
Brief Title
Vitamin D Supplementation Requirement in Obese Subjects
Official Title
Vitamin D Supplementation Requirement in Obese Subjects
Study Type
Interventional
2. Study Status
Record Verification Date
June 2023
Overall Recruitment Status
Terminated
Why Stopped
Enable to further recruit study subjects
Study Start Date
December 2008 (undefined)
Primary Completion Date
August 2013 (Actual)
Study Completion Date
August 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Winthrop University Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Vitamin D deficiency is common in obese patients. Most of vitamin D supplementation studies were done with non-obese subjects. This study looks at vitamin D supplementation requirements in obese patients as compared to non-obese subjects. This study also looks at changes in vitamin D level in obese patients undergoing medical weight loss. It is thought that obese patients have vitamin D deficiency through storage of vitamin D in the fat compartment not readily available for blood measurement. The investigators' hypothesis is that with medical weight loss vitamin D levels will increase in obese subjects.
Detailed Description
We intend to study changes in serum 25(OH)D level with calorie restricted weight loss in obese subjects. This will be a double dummy, placebo controlled randomized trial. Subjects whose serum 25(OH)D level is below 80 nmol/L will be assigned randomly to either the vitamin D supplemented or the placebo group. Those who are assigned to the placebo group will be weighed on a weekly basis and serum 25(OH)D level will be followed every 8 weeks for a minimum of 16 weeks and extended to the duration of weight loss along with serum calcium level. Changes in serum 25(OH)D level will be obtained with weight loss through restricted caloric intake.
To study the 25(OH)D dose-response curve with vitamin D supplementation in obese subjects, vitamin D supplemented group will receive initial daily vitamin D3 supplementation dose based on their baseline serum 25(OH)D level as described in Methods and Procedures section. Serum 25(OH)D levels will be drawn at 8 weeks and adjustments to the dose will be made based on the an algorithm to achieve serum 25(OH)D levels between 80 and 140 nmol/L. The dose-response curve obtained at 8 weeks will be compared to the one already established with non-obese subjects. Serum 25(OH)D level will be obtained at 16 weeks and compared with the data available from non-obese subjects.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vitamin D Deficiency
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
27 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Half of subjects will be randomized to the placebo group.
Arm Title
Vitamin D3
Arm Type
Active Comparator
Arm Description
This is the study group that receives Vitamin D supplementation.
Intervention Type
Drug
Intervention Name(s)
Vitamin D3
Intervention Description
Vitamin D supplementation will follow an algorithm for initial vitamin D dosing and for dose changes. Subjects will receive 100 ug/day of vitamin D3 if their 25(OH)D level is less than 50nmol/L and 50 ug/day if their 25(OH)D level is between 50 and 80 ug/day.
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
The placebo group will receive sugar pills appearing similar to the vitamin D capsules.
Primary Outcome Measure Information:
Title
Mean Level of 25(OH)D
Description
Vitamin D (25(OH)D) level at Baseline.
Time Frame
Baseline
Title
Mean Level of 25(OH)D
Description
Vitamin D (25(OH)D) level at Month 2.
Time Frame
Week 8
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Healthy men or women between the ages of 18 and 70 years old who are enrolled in our Weight Management Program with baseline BMI > 30 Kg/m2.
Exclusion Criteria:
Pregnancy,
Serum 25(OH)D level greater than 80 nmol/L,
Hypercalcemia (serum calcium level greater than the upper limit of normal),
Recent surgery or illness,
Those with chronic use of medications that influence calcium/vitamin D metabolism such as anti-convulsants, lithium and steroids. Thiazide diuretics for hypertension will be acceptable.
Subjects with sarcoidosis will be excluded.
Those who do not qualify to participate in the Weight Management Program will be excluded. They include subjects with active substance abuse and unstable cardiac disease.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
John Aloia,, MD
Organizational Affiliation
Winthrop-Unviersity Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Winthrop University Hospital
City
Mineola
State/Province
New York
ZIP/Postal Code
11501
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Vitamin D Supplementation Requirement in Obese Subjects
We'll reach out to this number within 24 hrs